[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]
- PMID:7481341
[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]
Abstract
We describe a new, water-soluble formulation of levodopa plus benserazide (Madopar LIQ) for the treatment of Parkinson's disease. Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levodopa plus 12.5 mg benserazide. Pharmacokinetic data show that levodopa absorption is more rapid than with standard Madopar, resulting in a shorter time to peak plasma concentration. Other pharmacokinetic values are comparable to those obtained with the standard formulation. We discuss the clinical advantages of this new water-soluble formulation, particularly when the patient requires rapid onset of action for morning or circadian akinesia. The indications of this formulation in patients with dysphagia and in other clinical situations, e.g. during the postoperative period and for levodopa dosage adjustment in ambulatory care, are discussed.
Similar articles
- Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A.Contin M, et al.Clin Neuropharmacol. 1999 Nov-Dec;22(6):351-5.Clin Neuropharmacol. 1999.PMID:10626097Clinical Trial.
- [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W.Eichhorn TE, et al.Nervenarzt. 1995 Dec;66(12):933-41.Nervenarzt. 1995.PMID:8584079German.
- [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.Podiwinsky F, et al.Wien Klin Wochenschr. 1979 May 11;91(10):332-7.Wien Klin Wochenschr. 1979.PMID:452602Clinical Trial.German.
- [Parkinson's disease and pregnancy: case report and literature review].Routiot T, Lurel S, Denis E, Barbarino-Monnier P.Routiot T, et al.J Gynecol Obstet Biol Reprod (Paris). 2000 Sep;29(5):454-7.J Gynecol Obstet Biol Reprod (Paris). 2000.PMID:11011274Review.French.
- Recent advances in the treatment of Parkinson's disease.Martocci RJ.Martocci RJ.J Am Osteopath Assoc. 1975 Apr;74(8):730-41.J Am Osteopath Assoc. 1975.PMID:1092751Review.No abstract available.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Medical